



Genvinset[®]

HLA A29



EUROPEAN UNION
European Regional Development Fund
A WAY TO MAKE EUROPE

Molecular determination of HLA-A*29 alleles

Kit for detecting the HLA-A*29 alleles
by Real-Time PCR using TaqMan[®]
probes technology

About Genvinset[®] HLA A29 Real Time

Code NLM AA1601/24

Birdshot retinochoroidopathy (BSRC) is a rare, chronic, bilateral, posterior uveitis characterized by distinctive, multiple, hypopigmented choroidal and retinal lesions. Blurred vision and floaters are the most prevalent visual symptoms. Patients may also report dyschromatopsia and poor contrast sensitivity. Macular oedema or atrophy is the most common cause of the decline in visual acuity and 10% of patients are legally blind. Middle-aged Caucasians of northern European extraction are most afflicted. The pathogenesis is unknown, but the presence of HLA-A*29 alleles appears to confer a predisposition.

HLA-A*29 is present in as many as 7% of Caucasians and is subdivided into more than 20 subtypes—mostly A*29:02 in Caucasians and A*29:01 in Asians. It has been found that gene sequences from all patients and healthy individuals sharing the A*29:01 or A*29:02 subtype were identical.

Intended use

Genvinset® HLA A29 is a semi-automated *in vitro* diagnostic kit for the qualitative detection of the HLA-A*29 group of alleles in genomic DNA extracted from whole blood, associated with Birdshot retinochoroidopathy predisposition, by Real-Time PCR using TaqMan® probes technology.

Patients who can benefit from this determination are those referred by a specialist. The results of this test should not be the only ones on which the therapeutic decision is based and should be used as an aid in the diagnosis together with results of other markers of the disease.

The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in the Instructions for Use.

Workflow




Product Information

24 tests - Code NLM AA1601/24


DESCRIPTION: Genvinset® HLA A29 Real Time 24 test
CE-IVD certified (Notified Body 2797)

Results

HLA-A*29 positive sample



HLA-A*29 negative sample



Limitations

- See detected alleles in the document "HLA alleles detected_GVS-A29" at www.bdrdiagnostics.com
- Mutations or polymorphisms at annealing primer/probe sites are possible and may result in the lack of allele definition. Other technologies could be necessary to resolve the typing.
- Data and result interpretation should be revised by qualified personnel.
- This product is an auxiliary tool for the diagnosis of patients with suspected birdshot retinochoroidopathy. Use these results in conjunction with clinical data and results of other tests performed on the patient.



BLACKHILLS DIAGNOSTIC RESOURCES S.L.U.
SRN: ES-MF-000001091 (Spain) · FIC GVS-A29 Rev. 02



EXCLUSIVE DISTRIBUTOR

Nuclear Laser Medicine srl

Viale delle Industrie, 3 - 20049 Settala (Milan), ITALY
Tel. 02 952451 - Fax 02 95245237-8

Partita Iva 08763060152

segreteria@nlm.it - www.nlm.it